1. Expression of Pentose Phosphate Pathway-Related Proteins in Breast Cancer
   Junjeong Choi et al, 2018, Disease Markers CrossRef
2. The metabolic landscape of urological cancers: New therapeutic perspectives
   Vera Miranda-Gonçalves et al, 2020, Cancer Letters CrossRef
3. Zoledronic acid, an FPPS inhibitor, ameliorates liver steatosis through inhibiting hepatic de novo lipogenesis
   Qiaoli Tang et al, 2017, European Journal of Pharmacology CrossRef
4. One-Pot Analytical Pipeline for Efficient and Sensitive Proteomic Analysis of Extracellular Vesicles
   Yi-Kai Liu et al, 2023, Journal of Proteome Research CrossRef
5. Cancer combination therapies with artemisinin-type drugs
   Thomas Efferth, 2017, Biochemical Pharmacology CrossRef
6. The Multiple Roles of Glucose-6-Phosphate Dehydrogenase in Tumorigenesis and Cancer Chemoresistance
   Jiaqi Song et al, 2022, Life CrossRef
7. Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival
   Jessica Whitburn et al, 2022, Science Advances CrossRef
8. Exosomal Long Non-Coding Ribonucleic Acid Ribonuclease Component of Mitochondrial Ribonucleic Acid Processing Endoribonuclease Is Defined as a Potential Non-Invasive Diagnostic Biomarker for Bladder Cancer and Facilitates Tumorigenesis via the miR-206/G6PD Axis
   Yuting Gao et al, 2023, Cancers CrossRef
9. Are we still on the right path(way)?: the altered expression of the pentose phosphate pathway in solid tumors and the potential of its inhibition in combination therapy
   Caroline J.W. Meskers et al, 2022, Expert Opinion on Drug Metabolism & Toxicology CrossRef
10. M4IDP stimulates ROS elevation through inhibition of mevalonate pathway and pentose phosphate pathway to inhibit colon cancer cells
    Ying Peng et al, 2023, Biochemical Pharmacology CrossRef
11. Targeting glucose‐6‐phosphate dehydrogenase by 6‐AN induces ROS‐mediated autophagic cell death in breast cancer
    Yin Li et al, 2023, The FEBS Journal CrossRef
12. The Emerging Roles of the Metabolic Regulator G6PD in Human Cancers
    Alfar Ahamed et al, 2023, International Journal of Molecular Sciences CrossRef
13. Combination Therapies of Artemisinin and its Derivatives as a Viable Approach for Future Cancer Treatment
    Maushmi S. Kumar et al, 2019, Current Pharmaceutical Design CrossRef
14. Enzyme targeting strategies for prevention and treatment of cancer: Implications for cancer therapy
    Mohammad Hassan Baig et al, 2019, Seminars in Cancer Biology CrossRef
15. Glucose-6-phosphate dehydrogenase: a therapeutic target for ovarian cancer
    Chenxi Wang et al, 2023, Expert Opinion on Therapeutic Targets CrossRef
16. Biochanin A – A G6PD inhibitor: In silico and in vitro studies in non-small cell lung cancer cells (A549)
    Anjali B. Thakkar et al, 2024, Toxicology in Vitro CrossRef
17. Targeting Energy Metabolism in Cancer Treatment
    Joanna Kubik et al, 2022, International Journal of Molecular Sciences CrossRef
18. G6PD: A hub for metabolic reprogramming and redox signaling in cancer
    Hung-Chi Yang et al, 2021, Biomedical Journal CrossRef
19. Metabolic phenotype of bladder cancer
    Francesco Massari et al, 2016, Cancer Treatment Reviews CrossRef
20. RIP kinase-mediated ROS production triggers XAF1 expression through activation of TAp73 in casticin-treated bladder cancer cells
    Yoon Hee Chung et al, 2016, Oncology Reports CrossRef
21. Differential Site-Based Expression of Pentose Phosphate Pathway-Related Proteins among Breast Cancer Metastases
    Yoon Jin Cha et al, 2017, Disease Markers CrossRef
22. The Redox Role of G6PD in Cell Growth, Cell Death, and Cancer
    null Yang et al, 2019, Cells CrossRef